These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 34160980)

  • 1. [Patent foramen ovale and stroke].
    Mas JL
    Rev Prat; 2021 Feb; 71(2):177-181. PubMed ID: 34160980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence.
    Mir H; Siemieniuk RAC; Ge L; Foroutan F; Fralick M; Syed T; Lopes LC; Kuijpers T; Mas JL; Vandvik PO; Agoritsas T; Guyatt GH
    BMJ Open; 2018 Jul; 8(7):e023761. PubMed ID: 30049703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients With Patent Foramen Ovale.
    Turc G; Lee JY; Brochet E; Kim JS; Song JK; Mas JL;
    J Am Coll Cardiol; 2020 May; 75(18):2312-2320. PubMed ID: 32381162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
    Mas JL; Derex L; Guérin P; Guillon B; Habib G; Juliard JM; Marijon E; Massardier E; Meneveau N; Vuillier F
    Arch Cardiovasc Dis; 2019; 112(8-9):532-542. PubMed ID: 31378692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design.
    Mas JL; Derumeaux G; Amarenco P; Arquizan C; Aubry P; Barthelet M; Bertrand B; Brochet E; Cabanes L; Donal E; Dubois-Randé JL; Durand-Zaleski I; Ernande L; Finet G; Fraisse A; Giroud M; Guérin P; Habib G; Juliard JM; Leys D; Lièvre M; Lusson JR; Marcon F; Michel P; Moulin T; Mounier-Vehier F; Pierard L; Piot C; Rey C; Rodier G; Roudaut R; Schleich JM; Teiger E; Turc G; Vuillier F; Weimar C; Woimant F; Chatellier G;
    Int J Stroke; 2016 Aug; 11(6):724-32. PubMed ID: 27056964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
    Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
    Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
    Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
    N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.
    Kent DM; Saver JL; Kasner SE; Nelson J; Carroll JD; Chatellier G; Derumeaux G; Furlan AJ; Herrmann HC; Jüni P; Kim JS; Koethe B; Lee PH; Lefebvre B; Mattle HP; Meier B; Reisman M; Smalling RW; Soendergaard L; Song JK; Mas JL; Thaler DE
    JAMA; 2021 Dec; 326(22):2277-2286. PubMed ID: 34905030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
    Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Closure of the patent foramen ovale (PFO) in cryptogenic stroke].
    Diener HC; Knebel F
    Herz; 2019 Jun; 44(4):304-309. PubMed ID: 30941472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprint of : Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
    Mas JL; Derex L; Guérin P; Guillon B; Habib G; Juliard JM; Marijon E; Massardier E; Meneveau N; Vuillier F
    Rev Neurol (Paris); 2020; 176(1-2):53-61. PubMed ID: 31787326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke.
    Smer A; Salih M; Mahfood Haddad T; Guddeti R; Saadi A; Saurav A; Belbase R; Ayan M; Traina M; Alla V; Del Core M
    Am J Cardiol; 2018 Jun; 121(11):1393-1399. PubMed ID: 29680170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term risk of atrial fibrillation or flutter after transcatheter patent foramen ovale closure: a nationwide Danish study.
    Skibsted CV; Korsholm K; Pedersen L; Bonnesen K; Nielsen-Kudsk JE; Schmidt M
    Eur Heart J; 2023 Sep; 44(36):3469-3477. PubMed ID: 37279491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of patent foramen ovale closure versus medical therapy for prevention of recurrent ischemic neurological events: Impact of medication type.
    Pan X; Xu L; Zhou C; Zhang Z; Sun H
    Medicine (Baltimore); 2021 Jun; 100(25):e26473. PubMed ID: 34160457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials.
    Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB
    Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
    J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.